These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9743458)

  • 1. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.
    Haarstad H; Lønning PE; Gundersen S; Wist E; Raabe N; Kvinnsland S
    Acta Oncol; 1998; 37(4):365-8. PubMed ID: 9743458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
    Buzdar A; Hayes D; El-Khoudary A; Yan S; Lønning P; Lichinitser M; Gopal R; Falkson G; Pritchard K; Lipton A; Wolter K; Lee A; Fly K; Chew R; Alderdice M; Burke K; Eisenber P;
    Breast Cancer Res Treat; 2002 May; 73(2):161-75. PubMed ID: 12088118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of droloxifene in patients with metastatic breast cancer.
    Buzdar AU; Kau S; Hortobagyi GN; Theriault RL; Booser D; Holmes FA; Walters R; Krakoff IH
    Cancer Chemother Pharmacol; 1994; 33(4):313-6. PubMed ID: 8281625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].
    Chevallier B; Spielmann M; Marty M; Serin D; Pouillart P; Tubiana Hulin M; Mignot L; Pujade Lauraine E; Krams M; Mertens H
    Bull Cancer; 1993 Jul; 80(7):624-8. PubMed ID: 8204943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group.
    Deschênes L
    Am J Clin Oncol; 1991; 14 Suppl 2():S52-5. PubMed ID: 1962599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
    Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
    Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study.
    Abe O
    Am J Clin Oncol; 1991; 14 Suppl 2():S40-5. PubMed ID: 1962596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.
    Arpino G; Nair Krishnan M; Doval Dinesh C; Bardou VJ; Clark GM; Elledge RM
    Ann Oncol; 2003 Feb; 14(2):233-41. PubMed ID: 12562650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droloxifene, a new antiestrogen: its role in metastatic breast cancer.
    Rauschning W; Pritchard KI
    Breast Cancer Res Treat; 1994; 31(1):83-94. PubMed ID: 7981460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
    Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
    J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European early phase II dose-finding study of droloxifene in advanced breast cancer.
    Bellmunt J; Solé L
    Am J Clin Oncol; 1991; 14 Suppl 2():S36-9. PubMed ID: 1962595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU;
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trials with toremifene in advanced breast cancer: a review.
    Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
    Geisler J; Ekse D; Hösch S; Lønning PE
    J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancer.
    Haarstad H; Gundersen S; Wist E; Raabe N; Mella O; Kvinnsland S
    Acta Oncol; 1992; 31(4):425-8. PubMed ID: 1632978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
    Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.